Biotricity's Health-Tech Boom Tempered by Market Jitters and Financial Warnings

REDWOOD CITY, CA – February 11, 2026 – Biotricity Inc. (OTCQB:BTCY), a company at the forefront of remote patient monitoring, today announced what appears to be a robust third quarter for fiscal 2026. The firm reported a 10.2% rise in revenue, expanding margins, and its third consecutive quarter of positive EBITDA. Yet, in a stark contrast that highlights the complex reality of the health-tech market, the company's stock tumbled over 16% in recent trading, and its own regulatory filings raise “substantial doubt” about its ability to continue as a going concern.

This paradox places Biotricity at a critical juncture: a company with a promising Technology-as-a-Service (TaaS) model and an innovative AI-driven vision for cardiac care, simultaneously grappling with severe financial pressures and investor skepticism.

The TaaS Paradox: Growth Meets Financial Scrutiny

On the surface, Biotricity's Q3 results paint a picture of a company executing its strategy effectively. Revenue for the quarter ending December 31, 2025, climbed to $4 million, up from $3.6 million in the prior-year period. More impressively, its gross margin swelled to 81.5%, a significant jump from 76.4% a year ago. The company credits this to the strength of its recurring revenue base and operational efficiencies gained from its proprietary AI.

These recurring technology fees, the core of its TaaS model, now account for 91.2% of total revenue, reaching $3.6 million for the quarter. This model, which provides continuous monitoring solutions to healthcare providers, has fostered impressive customer loyalty, with retention rates exceeding 90%. In a press release, Biotricity Founder & CEO, Dr. Waqaas Al-Siddiq, celebrated the results as a reflection of “continued revenue growth, sustained margins, and disciplined operational execution.”

However, a deeper look into the company's financial health reveals a more precarious situation. Recent SEC filings paint a starkly different picture from the optimistic press release. The filings disclose recurring losses that have led to an accumulated deficit of $142.1 million. As of December 31, 2025, the company reported a working capital deficit of $18.8 million and a cash balance of just $256,357. This combination of factors led management to include a “going concern” warning, a formal declaration that there is substantial doubt about the company's ability to operate for another year without securing additional funding.

The company has stated it plans to fund operations through revenue growth and by raising additional capital through equity and debt, but it offers no guarantee of success. This financial fragility stands in direct opposition to its operational achievements, creating a high-stakes environment where continued growth is not just a goal, but a necessity for survival.

AI at the Heart of the Strategy

At the center of Biotricity's strategy to outrun its financial troubles is a powerful technological asset: a sophisticated artificial intelligence platform. The company is on the verge of obtaining FDA clearance for a groundbreaking AI clinical model for its Cardiac AI Cloud platform. This AI has been trained on a massive dataset of over two trillion anonymized heartbeats, a scale intended to dramatically enhance diagnostic accuracy and efficiency for clinicians.

“Our approach allows providers to extend care beyond traditional touchpoints so they can serve more patients and improve outcomes without adding additional workload,” Dr. Al-Siddiq stated. He emphasized that the combination of this clinical AI with automation in operations enables the company to scale efficiently.

The impact is already being felt. The company attributes its expanding gross margins in part to these proprietary AI tools, which streamline operations and reduce costs. For customers, the promise is a higher quality of care, serving more patients, and opening new revenue streams for medical facilities. For Biotricity, it’s the key competitive advantage that could justify its valuation and attract the capital it desperately needs.

This technological push is part of a broader mission to address a looming public health crisis. The company highlights projections that cardiovascular disease will affect over 60% of the population in the next 30 years, at a cost of nearly $1.8 trillion. By shifting care from reactive treatment to proactive monitoring, Biotricity argues it can help prevent up to 80% of these cases, creating immense value across the healthcare ecosystem.

From Redwood City to Riyadh: A Global Ambition

While battling financial headwinds at home, Biotricity is simultaneously laying the groundwork for significant international expansion. The company has already secured regulatory approvals for its technologies in Canada, Saudi Arabia, and Argentina. These markets represent substantial new opportunities and are the first steps in establishing a global distribution network for its remote monitoring solutions.

This global perspective is essential to the company's long-term narrative. Cardiovascular disease is a worldwide problem, and a platform that proves effective and scalable in the U.S. has immense potential abroad. This expansion strategy, coupled with a growing domestic footprint across thousands of cardiologists, demonstrates a clear ambition to become a dominant player in chronic care management.

The company’s app user base has exploded from 4,500 to over 44,000 in just two years, illustrating strong adoption and the growing demand for accessible, continuous health monitoring. Biotricity is betting that this momentum, powered by its advanced AI and expanding market access, will convince investors that its vision for the future of healthcare is worth the risk. The coming months will be decisive, as the pursuit of FDA clearance for its AI and the urgent need for new capital converge, determining whether the company's technological promise can secure its financial future.